{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:56:34Z","timestamp":1791230194046,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijrobp.2023.12.052","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:27:14Z","timestamp":1704990434000},"page":"1061-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases"],"prefix":"10.1016","volume":"119","author":[{"given":"Marc","family":"Kerba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard De Abreu","family":"Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael De Feria","family":"Cardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten D","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina L.","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brundage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy R.","family":"Parulekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.12.052_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","article-title":"Palliative radiation therapy for bone metastases: Update of an ASTRO evidence-based guideline","volume":"7","author":"Lutz","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0002","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Palliative radiotherapy trials for bone metastases: A systematic review","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: An open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2022.05.043","article-title":"Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy","volume":"114","author":"Zeng","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijrobp.2014.10.055","article-title":"Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases","volume":"91","author":"Kim","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0006","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.ijrobp.2020.12.001","article-title":"Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial","volume":"109","author":"Qu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0007","doi-asserted-by":"crossref","first-page":"e1378","DOI":"10.1200\/JOP.19.00605","article-title":"Time-driven activity-based costing comparison of CT-guided versus MR-guided SBRT","volume":"16","author":"Parikh","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semradonc.2022.11.006","article-title":"Stereotactic body radiation therapy for spinal metastases: Benefits and limitations","volume":"33","author":"Guckenberger","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0009","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2014overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20141","volume":"15","author":"Caro","year":"2012","journal-title":"Value health"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0010","unstructured":"Canada's Drug and Health Technology Agency. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Accessed May 5, 2023."},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0011","article-title":"CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0012","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1524-4733.2007.00298.x","article-title":"The role of economic evidence in Canadian oncology reimbursement decision-making: To lambda and beyond","volume":"11","author":"Rocchi","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0013","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations","volume":"146","author":"Laupacis","year":"1992","journal-title":"CMAJ"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0014","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1259\/bjr.72.858.10560343","article-title":"The cost of radiotherapy as a function of facility size and hours of operation","volume":"72","author":"Dunscombe","year":"1999","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0360-3016(03)00579-0","article-title":"Activity-based costing: A practical model for cost calculation in radiotherapy","volume":"57","author":"Lievens","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0022","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.radonc.2005.07.003","article-title":"Costing the components of pain management: Analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): One versus five fractions for neuropathic bone pain","volume":"76","author":"Pollicino","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0017","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.9778\/cmajo.20170144","article-title":"The economic burden of cancer care in Canada: A population-based cost study","volume":"6","author":"de Oliveira","year":"2018","journal-title":"CMAJ Open"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0016","first-page":"95","article-title":"Estimating the cost of cancer care in British Columbia and Ontario: A Canadian inter-provincial comparison","volume":"12","author":"De Oliveira","year":"2017","journal-title":"Healthc Policy"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0018","first-page":"1","article-title":"Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: An economic analysis","volume":"16","year":"2016","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0019","article-title":"The EORTC QLU-C10D: The Canadian Valuation study and algorithm to derive cancer-specific utilities from the EORTC QLQ-C30","volume":"4","author":"McTaggart-Cowan","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0020","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-fraction versus multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 phase 2 randomized clinical trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0021","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ijrobp.2022.01.024","article-title":"Cost-effectiveness of single versus multifraction SABR for pulmonary oligometastases: The SAFRON II trial","volume":"114","author":"Lourenco","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/COC.0b013e31818da9f7","article-title":"Economic analysis of radiation therapy oncology group 97-14: Multiple versus single fraction radiation treatment of patients with bone metastases","volume":"32","author":"Konski","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0024","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jnci\/95.3.222","article-title":"Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: Cost-utility analysis based on a randomized trial","volume":"95","author":"van den Hout","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0026","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2014.02.012","article-title":"Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer","volume":"89","author":"Hodges","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0027","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djp518","article-title":"Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer","volume":"102","author":"Bradbury","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0028","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/jnci\/djp232","article-title":"Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial","volume":"101","author":"Mittmann","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.12.052_bib0029","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/cer.15.38","article-title":"Systematic overview of cost-effectiveness thresholds in ten countries across four continents","volume":"4","author":"Schwarzer","year":"2015","journal-title":"J Comp Eff Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T06:03:51Z","timestamp":1740204231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0360301624000221"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.052","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}